Vabysmo (faricimab) is the only bispecific antibody registered on the Australian Register of Therapeutic Goods (ARTG) for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO).1,2 It is listed also on the Pharmaceutical Benefits Scheme (PBS) for nAMD and DMO.3
This intravitreal treatment works on two distinct pathways, specifically recognising and blocking angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF).1 After four initial four-weekly loading doses, the frequency of ongoing injections may be extended up to every 16 weeks based on the patient’s anatomic and/or visual outcomes.1,4,5
Contact: Roche Account Manager
Mandatories
Please review the Product Information before prescribing, available at: roche-australia.com/ productinfo/vabysmo. Vabysmo ▼ is listed on the PBS for nAMD and DMO. Refer to PBS Schedule for full authority information and page 11 of this issue of mivision for indications.
▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at tga.gov.au/reporting-problems.
Prepared March 2024. M-AU-00002420.
References
- Vabysmo Approved Product Information. Available at roche-australia.com/productinfo/vabysmo.
- Australian Government Department of Health and Aged Care. Australian Register of Therapeutic Goods (ARTG). Available at: tga.gov.au/resources/artg [accessed 27 January 2023].
- Department of Health. Pharmaceutical Benefits Scheme. Available at pbs.gov.au.
- Heier, J.S., Khanani, A.M., Wong, T.Y., et al.; TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022 Feb 19;399(10326):729–740. DOI: 10.1016/S0140-6736(22)00010-1.
- Wykoff, C.C., Abreu, F., Tadayoni, R., et al., YOSEMITE and RHINE investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022 Feb 19;399(10326):741–755. DOI: 10.1016/S0140-6736(22)00018-6.
